These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 29868602)

  • 1. Mycophenolic Acid for Topical Immunosuppression in Vascularized Composite Allotransplantation: Optimizing Formulation and Preliminary Evaluation of Bioavailability and Pharmacokinetics.
    Feturi FG; Weinstock M; Zhao W; Zhang W; Schnider JT; Erbas VE; Oksuz S; Plock JA; Rohan L; Spiess AM; Ferreira LM; Solari MG; Venkataramanan R; Gorantla VS
    Front Surg; 2018; 5():20. PubMed ID: 29868602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and bioavailability of mycophenolic acid after intravenous administration and oral administration of mycophenolate mofetil to heart transplant recipients.
    Armstrong VW; Tenderich G; Shipkova M; Parsa A; Koerfer R; Schröder H; Oellerich M
    Ther Drug Monit; 2005 Jun; 27(3):315-21. PubMed ID: 15905802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings.
    Zucker K; Rosen A; Tsaroucha A; de Faria L; Roth D; Ciancio G; Esquenazi V; Burke G; Tzakis A; Miller J
    Transpl Immunol; 1997 Sep; 5(3):225-32. PubMed ID: 9402690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mycophenolic acid metabolite profile in renal transplant patients receiving enteric-coated mycophenolate sodium or mycophenolate mofetil.
    Tedesco-Silva H; Bastien MC; Choi L; Felipe C; Campestrini J; Picard F; Schmouder R
    Transplant Proc; 2005 Mar; 37(2):852-5. PubMed ID: 15848554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mycophenolate mofetil for solid organ transplantation: does the evidence support the need for clinical pharmacokinetic monitoring?
    Cox VC; Ensom MH
    Ther Drug Monit; 2003 Apr; 25(2):137-57. PubMed ID: 12657908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation.
    van Gelder T; Hilbrands LB; Vanrenterghem Y; Weimar W; de Fijter JW; Squifflet JP; Hené RJ; Verpooten GA; Navarro MT; Hale MD; Nicholls AJ
    Transplantation; 1999 Jul; 68(2):261-6. PubMed ID: 10440399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Compounded Topical Gabapentin for Neuropathic Pain: Does Choice of Base Affect Efficacy?
    Shakshuki A; Agu RU
    Int J Pharm Compd; 2019; 23(6):496-503. PubMed ID: 31751946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enteric-coated mycophenolate sodium delivers bioequivalent MPA exposure compared with mycophenolate mofetil.
    Arns W; Breuer S; Choudhury S; Taccard G; Lee J; Binder V; Roettele J; Schmouder R
    Clin Transplant; 2005 Apr; 19(2):199-206. PubMed ID: 15740555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients.
    Staatz CE; Tett SE
    Clin Pharmacokinet; 2007; 46(1):13-58. PubMed ID: 17201457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of mycophenolate mofetil in stable pediatric liver transplant recipients receiving mycophenolate mofetil and cyclosporine.
    Lobritto SJ; Rosenthal P; Bouw R; Leung M; Snell P; Mamelok RD
    Liver Transpl; 2007 Nov; 13(11):1570-5. PubMed ID: 17969194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and variability of mycophenolic acid from enteric-coated mycophenolate sodium compared with mycophenolate mofetil in de novo heart transplant recipients.
    Hummel M; Yonan N; Ross H; Miller LW; Sechaud R; Balez S; Koelle EU; Gerosa G;
    Clin Transplant; 2007; 21(1):18-23. PubMed ID: 17302587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
    Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
    Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure.
    Tett SE; Saint-Marcoux F; Staatz CE; Brunet M; Vinks AA; Miura M; Marquet P; Kuypers DR; van Gelder T; Cattaneo D
    Transplant Rev (Orlando); 2011 Apr; 25(2):47-57. PubMed ID: 21190834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vascularized composite allotransplantation versus solid organ transplantation: innate-adaptive immune interphase.
    Kadono K; Gruszynski M; Azari K; Kupiec-Weglinski JW
    Curr Opin Organ Transplant; 2019 Dec; 24(6):714-720. PubMed ID: 31577596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of mycophenolic acid in liver transplant patients after intravenous and oral administration of mycophenolate mofetil.
    Jain A; Venkataramanan R; Kwong T; Mohanka R; Orloff M; Abt P; Kashyap R; Tsoulfas G; Mack C; Williamson M; Batzold P; Bozorgzadeh A
    Liver Transpl; 2007 Jun; 13(6):791-6. PubMed ID: 17538999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics, efficacy, and safety of mycophenolate mofetil in combination with standard-dose or reduced-dose tacrolimus in liver transplant recipients.
    Nashan B; Saliba F; Durand F; Barcéna R; Herrero JI; Mentha G; Neuhaus P; Bowles M; Patch D; Bernardos A; Klempnauer J; Bouw R; Ives J; Mamelok R; McKay D; Truman M; Marotta P
    Liver Transpl; 2009 Feb; 15(2):136-47. PubMed ID: 19177449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Site-specific immunosuppression in vascularized composite allotransplantation: prospects and potential.
    Schnider JT; Weinstock M; Plock JA; Solari MG; Venkataramanan R; Zheng XX; Gorantla VS
    Clin Dev Immunol; 2013; 2013():495212. PubMed ID: 23476677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil.
    Mourad M; Malaise J; Chaib Eddour D; De Meyer M; König J; Schepers R; Squifflet JP; Wallemacq P
    Clin Chem; 2001 Jan; 47(1):88-94. PubMed ID: 11148182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pharmacokinetics of mycophenolate mofetil in Thai kidney transplant recipients.
    Jirasiritham S; Sumethkul V; Mavichak V; Na-Bangchang K
    Transplant Proc; 2004 Sep; 36(7):2076-8. PubMed ID: 15518751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. No relevant pharmacokinetic interaction between pantoprazole and mycophenolate in renal transplant patients: a randomized crossover study.
    Rissling O; Glander P; Hambach P; Mai M; Brakemeier S; Klonower D; Halleck F; Singer E; Schrezenmeier EV; Dürr M; Neumayer HH; Budde K
    Br J Clin Pharmacol; 2015 Nov; 80(5):1086-96. PubMed ID: 25913040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.